Advertisement

LAPTOP Study: A 24-Month Trial of Verteporfin Versus Ranibizumab for Polypoidal Choroidal Vasculopathy

Published:January 30, 2014DOI:https://doi.org/10.1016/j.ophtha.2013.12.037
      Age-related macular degeneration (AMD) is a leading cause of vision loss in developed countries. Polypoidal choroidal vasculopathy (PCV) is a subtype of AMD characterized by polypoidal lesions and a branching vascular network visualized with indocyanine green angiography. Although the first-line treatment for AMD is well-established, the optimal treatment for PCV can differ from that of AMD and remains under debate.
      • Kokame G.T.
      Polypoidal choroidal vasculopathy-an important diagnosis to make with therapeutic implications.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kokame G.T.
        Polypoidal choroidal vasculopathy-an important diagnosis to make with therapeutic implications.
        Retina. 2012; 32: 1446-1448
        • Koh A.H.
        • Chen L.J.
        • Chen S.J.
        • et al.
        Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment.
        Retina. 2013; 33: 686-716
        • Koh A.
        • Lee W.K.
        • Chen L.J.
        • et al.
        EVEREST STUDY: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
        Retina. 2012; 32: 1453-1464
        • Oishi A.
        • Kojima H.
        • Mandai M.
        • et al.
        Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
        Am J Ophthalmol. 2013; 156: 644-651
        • Fung A.E.
        • Lalwani G.A.
        • Rosenfeld P.J.
        • et al.
        An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
        Am J Ophthalmol. 2007; 143: 566-583

      Linked Article